R. Reife

Publications22
h-index17
Citations2,751
Highly Influential Citations73
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • G. Pledger
  • 89 Publications • 4,675 Citations
  • L. Kramer
  • 28 Publications • 3,121 Citations
  • R. Karim
  • 37 Publications • 2,199 Citations
  • S. Shorvon
  • 659 Publications • 28,154 Citations
  • Publications
  • Influence
Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages
TLDR
Results of this initial well-controlled study in patients indicate that topiramate is a very promising new AED.
View on Wolters Kluwer
Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages
TLDR
Topiramate is a highly efficacious and generally well tolerated new AED and incremental efficacy in the add-on setting is not observed at topiramate dosages above 600 mg/day; however, higher doses may prove beneficial to individual patients who tolerate them.
View on Publisher
A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome
TLDR
Topiramate adjunctive therapy was effective in reducing the number of drop attacks and major motor seizures and in improving seizure severity as determined by parental global evaluation.
View on Publisher
A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures
TLDR
Topiramate is well-tolerated and effective for the adjunctive treatment of PGTC seizures and treatment-limiting adverse events occurred in one patient in the topiramate group and one in the placebo group.
View on Publisher
Topiramate Monotherapy for Partial Onset Seizures
TLDR
Evaluation of topiramate as monotherapy in patients with uncontrolled partial onset seizures finds it safe and effective to use as a monotherapy.
View on Wiley
Topiramate as Add‐On Therapy: Pooled Analysis of Randomized Controlled Trials in Adults
Purpose: Six double‐blind, placebo‐controlled trials were conducted with topiramate (TPM) initiated as adjunctive therapy in adults with treatment‐resistant partial‐onset seizures with or without…
View on Wiley
Double‐Blind, Placebo‐Controlled Trial of Topiramate (600 mg Daily) for the Treatment of Refractory Partial Epilepsy
TLDR
Evaluating adjunctive therapy for partial‐onset seizures with topiramate with efficacy and safety in a double‐blind, placebo‐controlled, randomized, parallel‐group study found TPM to be safe and effective.
View on Wiley
Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy
View on Elsevier
Double‐Blind, Placebo‐Controlled Trial of Topiramate as Add‐on Therapy in Patients with Refractory Partial Seizures
TLDR
The present study further establishes the favorable profile and good benefithisk ratio of TPM in resistant partial epilepsy and confirms its use in patients with refractory partial epilepsy.
View on Wiley
A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children
TLDR
Topiramate was safe and effective in the treatment of partial-onset seizures in children in a multicenter, randomized, double-blind, placebo-controlled trial.
View on Publisher
...
...